: Checking if the patient might "shed" or spread the virus/vector through secretions.
The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459
: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells. 125459
For more detailed technical specifications, you can access the full Guideline on Non-Clinical Studies for GTMPs via the official .
This document outlines the essential safety and efficacy data that developers must generate during the "non-clinical" (animal or lab) phase to justify moving into human subjects. : Checking if the patient might "shed" or
: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy.
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA. For more detailed technical specifications, you can access
Guideline on the Non-Clinical Studies Required before First ... - EMA